The Role of the Family Physician in Achieving Optimal Outcomes in Moderate to Severe Atopic Dermatitis

 

 

PROGRAM OVERVIEW

Atopic dermatitis (AD) is frequently misdiagnosed in clinical practice due to a lack of standardized terminology and tests, causing inappropriate treatment of AD to also be widely prevalent in current clinical practice. In addition to gaps in patient care, financial burden and limitations to access may reduce the effectiveness of treatment in patients with AD. Several lines of evidence have confirmed that patients with moderate to severe AD report poor quality of life due to inadequately controlled disease. Primary care clinicians play a pivotal role in the management of patients with AD by referring patients with moderate to severe AD to a specialist, providing ongoing maintenance care after specialist evaluation, and managing patients with mild or more episodic AD themselves.

 

FACULTY

Eric L. Simpson, MD, MCR
Professor of Dermatology
Department of Dermatology
Oregon Health & Science University
Portland, Oregon

 

Release date: September 27, 2019
Expiration date: September 27, 2020
Estimated time to complete activity: 1.0 hour(s)

 

TARGET AUDIENCE

This educational initiative has been designed for family physicians, family nurse practitioners, and physician assistants involved in the management of patients with AD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Utilize updated criteria and guidelines to accurately diagnose AD
  • Assess and document disease severity in individual patients
  • Review updated guidelines and evaluate available clinical data for therapies utilized in the treatment of AD
  • Describe indications for specialist referral of patients with AD and review best practices for co-management of moderate to severe disease with specialist physicians
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 27, 2019 through September 27, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Eric L. Simpson, MD, MCR
Consulting Fees: AbbVie; Eli Lilly; Forte Bio Rx; Orhto Dermatologics; Pierre Fabre Dermo Cosmetiue; Pfizer; Sanofi Genzyme and Regeneron Pharmaceuticals
Contracted Research: AbbVie; Eli Lilly; Kyowa Hakko Kirin; Leo Pharma; Pfizer; Sanofi Genzyme and Regeneron Pharmaceuticals

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

 

Continue to Pretest